EA202192483A1 - Лекарственное средство и способ лечения или профилактики осложнений диабета с использованием этого лекарственного средства - Google Patents
Лекарственное средство и способ лечения или профилактики осложнений диабета с использованием этого лекарственного средстваInfo
- Publication number
- EA202192483A1 EA202192483A1 EA202192483A EA202192483A EA202192483A1 EA 202192483 A1 EA202192483 A1 EA 202192483A1 EA 202192483 A EA202192483 A EA 202192483A EA 202192483 A EA202192483 A EA 202192483A EA 202192483 A1 EA202192483 A1 EA 202192483A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- medicine
- complications
- diabetes
- prevention
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019044670 | 2019-03-12 | ||
| PCT/JP2020/010967 WO2020184691A1 (ja) | 2019-03-12 | 2020-03-12 | 薬剤及び該薬剤を用いて糖尿病合併症を治療又は予防する方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA202192483A1 true EA202192483A1 (ru) | 2021-12-24 |
Family
ID=72426033
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA202192483A EA202192483A1 (ru) | 2019-03-12 | 2020-03-12 | Лекарственное средство и способ лечения или профилактики осложнений диабета с использованием этого лекарственного средства |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20220218664A1 (https=) |
| EP (1) | EP3939659A4 (https=) |
| JP (1) | JPWO2020184691A1 (https=) |
| KR (1) | KR20220009371A (https=) |
| CN (1) | CN114126711A (https=) |
| AU (1) | AU2020238177A1 (https=) |
| BR (1) | BR112021018084A8 (https=) |
| CA (1) | CA3133204A1 (https=) |
| CL (1) | CL2021002373A1 (https=) |
| EA (1) | EA202192483A1 (https=) |
| IL (1) | IL286289A (https=) |
| MX (1) | MX2021011007A (https=) |
| PE (1) | PE20220333A1 (https=) |
| SG (1) | SG11202109982YA (https=) |
| WO (1) | WO2020184691A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220040294A (ko) * | 2020-09-23 | 2022-03-30 | 씨엔지바이오 주식회사 | 6-메톡시-2-펜에틸이소인돌린-1-온 유도체 및 이를 포함하는 신경질환의 치료용 조성물 |
| CN121064220A (zh) * | 2021-02-10 | 2025-12-05 | 福建盛迪医药有限公司 | 一种smtp-7衍生物及其用途 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05176782A (ja) * | 1992-01-08 | 1993-07-20 | Taisho Pharmaceut Co Ltd | Ｎｇｆ作用増強因子 |
| JP2004224737A (ja) | 2003-01-23 | 2004-08-12 | Ttc:Kk | 新規トリプレニルフェノール化合物 |
| JP4313049B2 (ja) * | 2003-01-23 | 2009-08-12 | 株式会社ティーティーシー | 血管新生関連疾患の予防又は治療用医薬組成物 |
| WO2007040082A1 (ja) | 2005-10-06 | 2007-04-12 | National University Corporation Tokyo University Of Agriculture And Technology | 腎炎治療又は予防用医薬組成物及びその製造方法 |
| CN102304131B (zh) | 2006-03-27 | 2014-07-16 | 农工大Tlo株式会社 | 三异戊二烯基酚化合物、三异戊二烯基酚化合物的制造方法和血栓溶解促进剂 |
| WO2010110026A1 (ja) * | 2009-03-25 | 2010-09-30 | 国立大学法人東京農工大学 | メタボリックシンドローム、肥満、高血糖症、高脂血症および／又は脂肪肝のための医薬組成物 |
| ES2476041T3 (es) * | 2009-07-06 | 2014-07-11 | National University Corporation Tokyo University Of Agriculture And Technology | Agente citoprotector trifenilfen�lico |
| WO2011125930A1 (ja) * | 2010-04-02 | 2011-10-13 | 日本製薬株式会社 | 炎症性腸疾患又は自己免疫性の末梢神経障害の予防又は治療剤 |
| WO2012115209A1 (ja) * | 2011-02-24 | 2012-08-30 | 国立大学法人東京農工大学 | 可溶性エポキシドハイドロラーゼ阻害剤 |
| JP2019044670A (ja) | 2017-08-31 | 2019-03-22 | スズキ株式会社 | 内燃機関の排出ガス浄化システム |
-
2020
- 2020-03-12 CN CN202080035808.7A patent/CN114126711A/zh active Pending
- 2020-03-12 PE PE2021001508A patent/PE20220333A1/es unknown
- 2020-03-12 WO PCT/JP2020/010967 patent/WO2020184691A1/ja not_active Ceased
- 2020-03-12 MX MX2021011007A patent/MX2021011007A/es unknown
- 2020-03-12 EA EA202192483A patent/EA202192483A1/ru unknown
- 2020-03-12 SG SG11202109982Y patent/SG11202109982YA/en unknown
- 2020-03-12 KR KR1020217032312A patent/KR20220009371A/ko not_active Withdrawn
- 2020-03-12 JP JP2021505150A patent/JPWO2020184691A1/ja not_active Withdrawn
- 2020-03-12 US US17/438,801 patent/US20220218664A1/en not_active Abandoned
- 2020-03-12 EP EP20771088.0A patent/EP3939659A4/en not_active Withdrawn
- 2020-03-12 AU AU2020238177A patent/AU2020238177A1/en not_active Abandoned
- 2020-03-12 BR BR112021018084A patent/BR112021018084A8/pt not_active Application Discontinuation
- 2020-03-12 CA CA3133204A patent/CA3133204A1/en active Pending
-
2021
- 2021-09-10 CL CL2021002373A patent/CL2021002373A1/es unknown
- 2021-09-12 IL IL286289A patent/IL286289A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3939659A1 (en) | 2022-01-19 |
| US20220218664A1 (en) | 2022-07-14 |
| EP3939659A4 (en) | 2022-12-21 |
| CL2021002373A1 (es) | 2022-06-17 |
| BR112021018084A8 (pt) | 2022-10-04 |
| SG11202109982YA (en) | 2021-10-28 |
| AU2020238177A1 (en) | 2021-11-04 |
| PE20220333A1 (es) | 2022-03-14 |
| CN114126711A (zh) | 2022-03-01 |
| CA3133204A1 (en) | 2020-09-17 |
| IL286289A (en) | 2021-10-31 |
| WO2020184691A1 (ja) | 2020-09-17 |
| JPWO2020184691A1 (https=) | 2020-09-17 |
| BR112021018084A2 (https=) | 2021-12-21 |
| MX2021011007A (es) | 2022-03-11 |
| KR20220009371A (ko) | 2022-01-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020551821A1 (en) | Novel compounds | |
| EA202090955A1 (ru) | Способы применения ингибиторов ehmt2 в лечении или предупреждении нарушений со стороны крови | |
| MX2023007853A (es) | Compuesto heterociclico puenteado que contiene nitrogeno, metodo de preparacion y uso medico del mismo. | |
| EA202193007A1 (ru) | Соединения пирролидина | |
| MY209310A (en) | Sting agonistic compound | |
| EP4424315A3 (en) | Novel compounds | |
| EA202090573A1 (ru) | Составы нирапариба | |
| EA202090688A1 (ru) | Бис-амидные соединения, активирующие саркомер, и варианты их применения | |
| EA201891103A1 (ru) | Композиции для лечения спинальной мышечной атрофии | |
| EA202192433A1 (ru) | Соединения, полезные в терапии вич | |
| MX2023006504A (es) | Compuesto de hidroxamato, metodo de preparacion del mismo y aplicacion del mismo. | |
| PH12021550713A1 (en) | Medicament for the treatment of chronic cough | |
| AU2020288567A8 (en) | Pyrrolopyrimidine compound and use thereof | |
| EA201992272A1 (ru) | Ацилированное инсулиновое соединение | |
| PH12020500556A1 (en) | Nitrogen-containing six-membered ring compound | |
| EA202091400A1 (ru) | Производные пиррола в качестве ингибиторов асс | |
| MX391911B (es) | Compuesto antimicrobiano ((2r,3s,5r)-5-(4-amino-2-oxopirimidin-1(2h)- il)-3-((butoxióxidofosfor-il)oxi) tetrahidrofuran-2-il)metil butil fosfato, y el uso del mismo en infecciones. | |
| PH12020551117A1 (en) | Compositions for preventing or treating uveitis | |
| EA202192483A1 (ru) | Лекарственное средство и способ лечения или профилактики осложнений диабета с использованием этого лекарственного средства | |
| EA202190064A1 (ru) | Цианотриазоловые соединения и варианты их применения | |
| MX2020014262A (es) | Composicion farmaceutica que comprende un agente basico poco soluble. | |
| JOP20170040B1 (ar) | مركب لخفض جلوكوز الدم | |
| EA201990550A1 (ru) | Офтальмологический препарат, включающий азоловое соединение | |
| MX2022012033A (es) | Agente terapeutico para infeccion por coronavirus. | |
| EA202190317A1 (ru) | Лекарственный препарат для наружного применения |